447 related articles for article (PubMed ID: 29255415)
41. Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs.
Jin Q; Chen D; Zhang X; Zhang F; Zhong D; Lin D; Guan L; Pan W; Zhou D; Ge J
Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376028
[TBL] [Abstract][Full Text] [Related]
42. Current therapeutics and practical management strategies for pulmonary arterial hypertension.
Agarwal R; Gomberg-Maitland M
Am Heart J; 2011 Aug; 162(2):201-13. PubMed ID: 21835279
[TBL] [Abstract][Full Text] [Related]
43. Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding.
Rai N; Veeroju S; Schymura Y; Janssen W; Wietelmann A; Kojonazarov B; Weissmann N; Stasch JP; Ghofrani HA; Seeger W; Schermuly RT; Novoyatleva T
Biomed Res Int; 2018; 2018():3293584. PubMed ID: 29511676
[TBL] [Abstract][Full Text] [Related]
44. [Adenosine receptors agonists mitigated PAH of rats induced by chronic hypoxia through reduction of renin activity/angiotensin II levels and increase of inducible nitric oxide synthase-nitric oxide levels].
Tan JX; Huang XL; Wang B; Fang X; Huang DN
Zhonghua Er Ke Za Zhi; 2012 Oct; 50(10):782-7. PubMed ID: 23302571
[TBL] [Abstract][Full Text] [Related]
45. [Evolution of pathogenetic therapy of pulmonary arterial hypertension].
Chazova IE; Yarovoy SY; Danilov NM
Ter Arkh; 2019 Dec; 91(12):4-9. PubMed ID: 32598582
[TBL] [Abstract][Full Text] [Related]
46. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication.
Guignabert C; Tu L; Girerd B; Ricard N; Huertas A; Montani D; Humbert M
Chest; 2015 Feb; 147(2):529-537. PubMed ID: 25644906
[TBL] [Abstract][Full Text] [Related]
47. Immunotherapy of Endothelin-1 Receptor Type A for Pulmonary Arterial Hypertension.
Dai Y; Chen X; Song X; Chen X; Ma W; Lin J; Wu H; Hu X; Zhou Y; Zhang H; Liao Y; Qiu Z; Zhou Z
J Am Coll Cardiol; 2019 May; 73(20):2567-2580. PubMed ID: 31118151
[TBL] [Abstract][Full Text] [Related]
48. Magnolol ameliorates pneumonectomy and monocrotaline-induced pulmonary arterial hypertension in rats through inhibition of angiotensin II and endothelin-1 expression.
Chang H; Chang CY; Lee HJ; Chou CY; Chou TC
Phytomedicine; 2018 Dec; 51():205-213. PubMed ID: 30466619
[TBL] [Abstract][Full Text] [Related]
49. ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension.
Budas GR; Boehm M; Kojonazarov B; Viswanathan G; Tian X; Veeroju S; Novoyatleva T; Grimminger F; Hinojosa-Kirschenbaum F; Ghofrani HA; Weissmann N; Seeger W; Liles JT; Schermuly RT
Am J Respir Crit Care Med; 2018 Feb; 197(3):373-385. PubMed ID: 28910144
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.
Spieker LE; Noll G; Lüscher TF
Am J Cardiovasc Drugs; 2001; 1(4):293-303. PubMed ID: 14728028
[TBL] [Abstract][Full Text] [Related]
51. Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center.
Sulica R; Fenton R; Cefali F
Cardiol Ther; 2015 Dec; 4(2):209-18. PubMed ID: 26411969
[TBL] [Abstract][Full Text] [Related]
52. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management.
Ramirez A; Varga J
Treat Respir Med; 2004; 3(6):339-52. PubMed ID: 15658881
[TBL] [Abstract][Full Text] [Related]
53. Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy.
Lyle MA; Davis JP; Brozovich FV
Front Physiol; 2017; 8():614. PubMed ID: 28878690
[TBL] [Abstract][Full Text] [Related]
54. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases.
Abbracchio MP; Cattabeni F
Ann N Y Acad Sci; 1999; 890():79-92. PubMed ID: 10668415
[TBL] [Abstract][Full Text] [Related]
55. Stage‑dependent changes of β2‑adrenergic receptor signaling in right ventricular remodeling in monocrotaline‑induced pulmonary arterial hypertension.
Sun F; Lu Z; Zhang Y; Geng S; Xu M; Xu L; Huang Y; Zhuang P; Zhang Y
Int J Mol Med; 2018 May; 41(5):2493-2504. PubMed ID: 29393391
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic effect of prostaglandin E1 in monocrotaline-induced pulmonary arterial hypertension rats.
Lee JC
Anat Cell Biol; 2017 Mar; 50(1):60-68. PubMed ID: 28417056
[TBL] [Abstract][Full Text] [Related]
57. Mitochondrial dynamics in pulmonary arterial hypertension.
Ryan J; Dasgupta A; Huston J; Chen KH; Archer SL
J Mol Med (Berl); 2015 Mar; 93(3):229-42. PubMed ID: 25672499
[TBL] [Abstract][Full Text] [Related]
58. The pharmacological treatment of pulmonary arterial hypertension.
Frumkin LR
Pharmacol Rev; 2012 Jul; 64(3):583-620. PubMed ID: 22659328
[TBL] [Abstract][Full Text] [Related]
59. Targeted activation of endothelin-1 exacerbates hypoxia-induced pulmonary hypertension.
Satwiko MG; Ikeda K; Nakayama K; Yagi K; Hocher B; Hirata K; Emoto N
Biochem Biophys Res Commun; 2015 Sep; 465(3):356-62. PubMed ID: 26275708
[TBL] [Abstract][Full Text] [Related]
60. Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension.
Mendes-Ferreira P; Maia-Rocha C; Adão R; Mendes MJ; Santos-Ribeiro D; Alves BS; Cerqueira RJ; Castro-Chaves P; Lourenço AP; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
Cardiovasc Res; 2016 Jan; 109(1):44-54. PubMed ID: 26503987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
